7 results about "Secretagogue" patented technology

Described herein are amino acid formulations useful for treating diarrhea in subjects in need thereof. Such amino acid formulations and methods comprising administering the amino acid formulations to a subject can be used to treat diarrhea, particularly diarrhea caused by or associated with a bacterial infection, wherein secretagogue-stimulated anion secretion from the intestinal crypts results in at least one diarrheal symptom in the subject. Contemplated herein are the use of these amino acid formulations for treating diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypts, and their use in the preparation of a medicament for treating diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypts.

The invention relates to design, preparation and application of a double-target compound which has activity on both a human glucagon-like peptide-1 receptor (GLP-1R) and a KCNH6 potassium channel. The compound plays a dual role of a GLP-1 receptor agonist and an endogenous GLP-1 secretagogue by activating GLP-1R and blocking KCNH6, and can be used for treating obesity, type 2 diabetes mellitus and related complications thereof.

To provide a secretion promoter that promotes the secretion of oxytocin by an organism and can increase the amount of oxytocin to a proper level and a method for producing the same.SOLUTION: The present invention provides a method for producing a secretion promoter that promotes the secretion of oxytocin. The production method includes a first step of collecting a first smell component secreted from an infant and a second smell component secreted from a mother in a nursing period, a second step of comparing the first smell component with the second smell component to identify, among substances contained in the first smell component, a substance whose secretion is less than 0.05 as a q value in FDR (False Discovery Rate) relative to the secretion of substances contained in the second smell component, or a substance having a p value in FWER (Family-Wise Error Rate) of less than 0.05, as a characteristic substance, and a third step of producing a secretion promoter on the basis of the characteristic substance.SELECTED DRAWING: Figure 1

The invention relates to the technical field of biological medicines, in particular to application of parthenolide and / or parthenolide derivatives in preparation of medicines for preventing and / or treating diabetes mellitus and in preparation of products for body weight intervention and / or blood sugar maintenance. The bitter compound parthenolide can be obtained from a natural product and is safe in component, the binding energy of parthenolide and GLP1R on the atomic level is-6.3 kcal / mol, parthenolide can serve as a GLP-1 receptor agonist and can promote GLP-1 secretion, the onset concentration of parthenolide is low (15-30 [mu] M), and it is indicated that parthenolide serves as a receptor to excite the secretion of intestinal peptide hormone, and the titer intensity of parthenolide is high. Therefore, parthenolide and / or parthenolide derivatives are / is a secretagogue which efficiently secretes GLP-1 and is low in side effect, are / is a promising direction for improving the endogenous GLP-1 level, provide a good scientific basis for developing products for effectively intervening body weight and maintaining the blood sugar health level in the future, and have great potential market value.

Amino acid formulations useful for treating diarrhea in a subject in need thereof are described herein. Such amino acid formulations and methods comprising administering same to a subject are useful for treating diarrhea, particularly diarrhea caused by or associated with bacterial infections wherein secretagogue-stimulated anion secretion from the intestinal crypt contributes to at least one symptom of diarrhea in the subject. Use of these amino acid formulations for the treatment of diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypt are encompassed herein, as are their use in the preparation of a medicament for the treatment of diarrhea in general or diarrhea associated with secretagogue-stimulated anion secretion from the intestinal crypt.

A method of slowing the weight regain after cessation of an anorectic drug (GLP-1 analog) where a coion targeted gut hormone secretagogue is administered.

This invention relates to the application of secretin in the preparation of drugs for treating steatohepatitis associated with metabolic dysfunction, belonging to the field of biomedical technology. This invention provides the application of secretin in the preparation of drugs for treating steatohepatitis associated with metabolic dysfunction. Cell model, gene knockout, in vivo complementation, and exogenous protein intervention experiments were conducted, revealing that secretin has significant in vitro and in vivo protective effects against steatohepatitis associated with metabolic dysfunction. In vitro, secretin can significantly improve oleic acid-induced lipid accumulation in hepatocytes, inhibit abnormal accumulation of lipid droplets in hepatocytes, reduce the expression of inflammatory factors in hepatocytes, alleviate hepatocyte inflammatory damage caused by lipotoxicity, and enter hepatocytes through endocytosis. It can alleviate high-fat diet-induced hepatic steatosis and inflammatory infiltration in MASH mice, and reduce the degree of liver fibrosis.